RT Journal Article
T1 Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia 5-Year SAFEHEART Registry Follow-Up
A1 Perez-de-Isla, Leopoldo
A1 Alonso, Rodrigo
A1 Watts, Gerald F.
A1 Mata, Nelva
A1 Saltijeral-Cerezo, Adriana
A1 Muniz, Ovidio
A1 Fuentes, Francisco
A1 Diaz-Diaz, Jose Luis
A1 de-Andres, Raimundo
A1 Zambon, Daniel
A1 Rubio-Marin, Patricia
A1 Barba-Romero, Miguel A.
A1 Saenz, Pedro
A1 Sanchez-Munoz-Torrero, Juan F.
A1 Martinez-Faedo, Ceferino
A1 Miramontes-Gonzalez, Jose P.
A1 Badimon, Lina
A1 Mata, Pedro
K1 Guidance
K1 Management
K1 Ezetimibe
K1 Mortality
K1 Efficacy
K1 Therapy
K1 Disease
K1 Cohort
K1 Risk
K1 Care
K1 Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
K1 Cardiovascular disease
K1 LDL-receptor mutations
K1 Lipid-lowering therapy
K1 Low-density lipoprotein cholesterol
AB BACKGROUND Familial hypercholesterolemia (FH) is the most common genetic disorder associated with premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data on attainment of treatment targets; large registries that reflect real-life clinical practice can uniquely provide this information.OBJECTIVES We sought to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients enrolled in a large national registry.METHODS The SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) is a large, ongoing registry of molecularly defined patients with heterozygous FH treated in Spain. The attainment of guideline-recommended plasma LDL-C goals at entry and follow-up was investigated in relation to use of lipid-lowering therapy (LLT).RESULTS The study recruited 4,132 individuals (3,745 of whom were >= 18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 +/- 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target = 18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 +/- 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target <100 mg/dl was reached by only 11.2% of patients. At follow-up, there was a significant increasein the use of ezetimibe, drug combinations with statins, and maximal LLT. The presence of type 2 diabetes mellitus, adefective allele mutation, ezetimibe use, and the absence of previous ASCVD were predictors of the attainment ofLDL-C  goals. CONCLUSIONS Despite the use of intensified LLT, many FH patients continue to experience high plasma LDL-C levelsand, consequently, do not achieve recommended treatment targets. Type of LDL-receptor mutation, use of ezetimibe,coexistent diabetes, and ASCVD status can bear significantly on the likelihood of attaining LDL-C treatment goals.
PB Elsevier
SN 0735-1097
YR 2016
FD 2016-01-05
LK http://hdl.handle.net/10668/18806
UL http://hdl.handle.net/10668/18806
LA en
NO Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, et al. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. J Am Coll Cardiol. 2016 Mar 22;67(11):1278-85
DS RISalud
RD Jul 7, 2025